PAR 0.00% 21.0¢ paradigm biopharmaceuticals limited..

Lorecivivint, page-7

  1. 1,668 Posts.
    lightbulb Created with Sketch. 179
    I flagged in August that Lorecivivint could be a
    worthy rival, but was told by the bias confirmers
    that it would not cut the mustard, although I was
    never given a good reason why.

    They certainly have the jump on us timewise,
    by about 2-3 years. P3 results due late this
    year. Also it appears they have considerable
    financial backing.

    Lets hope FDA gives them considerably more
    homework.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.